0R15 7603.0 -1.7651% 0R1E 7406.0 -1.3848% 0M69 None None% 0R2V 168.75 -0.8811% 0QYR 1341.134 1.2177% 0QYP 392.5 -4.0342% 0LCV 132.52 -0.8084% 0RUK 2940.0 0.616% 0RYA 1742.0 -2.1348% 0RIH 157.95 -0.2211% 0RIH 155.51 -1.5448% 0R1O 171.25 9561.4951% 0R1O None None% 0QFP 8920.4336 76.9927% 0M2Z 296.7062 -0.5009% 0VSO 23.61 -33.6891% 0R1I None None% 0QZI 492.5 -0.1014% 0QZ0 220.0 0.0% 0NZF 859.0151 72.3546%

UK Technical Analysis Report

FTSE All-Share Traded mixed, Two LSE Listed Stocks to Gain Upside Momentum – PMG & POLB

Mar 12, 2024

PMG:LSE
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (GBX)
POLB:LSE
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (GBX)

This report is an updated version of the report published on 12 March 2024 at 07:55 AM GMT.

Company Overview: Parkmead Group PLC (LON: PMG) is a FTSE AIM All Shares listed United Kingdom-based independent energy company focused on the United Kingdom and Netherlands and produces natural gas from a portfolio of four fields across the Netherlands, the United Kingdom, and Dutch sectors. The Company operates the Greater Perth Area (GPA) oil hub project in the United Kingdom Moray Firth. In addition, the Company has stakes in other oil and gas developments in the Netherlands. It holds a 7.5% to 15% working interest in four producing onshore gas fields in the Netherlands: Geesbrug, Brakel, Grolloo and Diever West. Poolbeg Pharma PLC (LON: POLB): is a FTSE AIM All Shares listed United Kingdom-based biopharmaceutical company, engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company engages in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 002 and POLB 003. This Report covers the Price Action, Technical Indicators Analysis along with the Target Levels, Stop Loss, Support Levels, Resistance Levels, and Recommendations on the stock.

FTSE All-Share Index (.FTAS) Market Round-Up

Last week, the benchmark FTSE All-Share Index (.FTAS) started slightly negatively and recovered from low and remained in rangebound direction for the entire week. The index made a low of 4154.98 during the week and settled at 4194.47, with a loss of ~0.13 percent for the week ending March 8, 2024. The recent week started with a positive note along with the global market trend and closed at 4196.01 level.

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions